Over the past two decades, significant progress in understanding of the pathogenesis of type
2 chronic inflammatory diseases has enabled the identification of compounds for more than …

The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway
is an evolutionarily conserved mechanism of transmembrane signal transduction that …

Janus kinase (JAK) inhibitors have been recently approved by the FDA and are widely used
in the treatment of patients with atopic dermatitis. However, a comprehensive safety profile of …

Type 2 inflammation is characterized by overexpression and heightened activity of type 2
cytokines, mediators and cells that drive neuroimmune activation and sensitization to …

The JAK-STAT signaling pathway mediates important cellular processes such as immune
response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that …

Atopic dermatitis represents a complex and multidimensional interaction that represents
potential fields of preventive and therapeutic management. In addition to the treatment …

Upadacitinib is a selective Janus kinase (JAK) inhibitor which is approved by the US Food
and Drug Administration, the European Medicines Agency, as well as other agencies …

Background Abrocitinib is a JAK‐1 selective inhibitor registered for the treatment of
moderate‐to‐severe atopic dermatitis (AD). Although efficacy and safety have been shown …

Abstract Spinal Cord Injury (SCI) is a devastating neurological disorder comprising primary
mechanical injury and secondary inflammatory response-mediated injury for which an …

Several studies have reported the pathogenic role of Malassezia in atopic dermatitis (AD);
the significance of Malassezia's influence on AD needs to be further investigated …